# Evaluation of the Effectiveness and Safety of Remote Electrocardiographic Monitoring in Patients with Atrial Fibrillation Following Ablation Therapy

Study · id `cardio:ct-nct06751459` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06751459](<https://clinicaltrials.gov/study/NCT06751459>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06751459

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 270 participants.

## Technical summary

Registry record NCT06751459. Randomized; no masking; primary purpose supportive care. Start 2025-01-06 (anticipated); primary completion 2026-08-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose supportive care
- Phase: Not applicable
- Enrolled: 270 participants (planned count; ClinicalTrials.gov record NCT06751459, source copy `cardio:ctgov-nct06751459-2024-12-31`, retrieved 2026-10-26)
- Planned start: 2025-01-06 (anticipated) (ClinicalTrials.gov record NCT06751459, source copy `cardio:ctgov-nct06751459-2024-12-31`, retrieved 2026-10-26)
- Primary completion: 2026-08-01 (anticipated) (ClinicalTrials.gov record NCT06751459, source copy `cardio:ctgov-nct06751459-2024-12-31`, retrieved 2026-10-26)
- Completion: 2027-03-01 (anticipated) (ClinicalTrials.gov record NCT06751459, source copy `cardio:ctgov-nct06751459-2024-12-31`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06751459, source copy `cardio:ctgov-nct06751459-2024-12-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06751459-2024-12-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of the Effectiveness and Safety of Remote Electrocardiographic Monitoring in Patients with Atrial Fibrillation Following Ablation Therapy
- Acronym: PREEMPT-AF
- Condition: Atrial Fibrillation (AF)
- Intervention (Device): MEMO Patch 2 - 14-day Monitoring
- Intervention (Device): MEMO Patch 2 - 1-day Monitoring
- Intervention (Device): MEMO Link
- Lead sponsor: HUINNO Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)

## Provenance

Content hash: 2a5bc1e9f324d56fa6d002ce5c73e6f292933b1ff7031bf7a6169ed409c6dc6c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
